Latest Alzheimer’s drug shown less effective in females than males

Since becoming only the second Alzheimer’s-modifying drug to gain American FDA approval in 2023, sales of lecanemab, known by its brand name Leqembi, have risen steadily, reaching $87-million USD...

• Read more about Latest Alzheimer’s drug shown less effective in females than males